Fast Facts
Indicated for intravenous intra-arterial body cavity intrathecal & gastrointestinal studies5
98% of paediatric patients undergoing abdominal CT, many of whom were under the age of five, drank the required volume of diluted Omnipaque3
Every 2 seconds, 3 procedures utilise Omnipaque1
The only low osmolar contrast agent on the WHO essential drug list1
Omnipaque is approved for use in both adults and children9
Omnipaque has been used in over 690 million procedures to date2
+PLUSPAK™ efficiency helps in reducing costs & environmental impact, and hazards6-8
No LOCM was better tolerated than Omnipaque in a prospective randomized study of 8,931 CT patients4
Prescribing Information
- WHO Model List of Essential Medicines, 20th List, August 2017
- Data on File, GE Healthcare_Usage
- Smevik B, Westvik J. Acta Radiol 1990; 31(6): 601-4.
- Gomi T et al. Eur Radiol 2010; 20(7): 1631-5.
- Omnipaque Summary of Product Characteristics, July 2016
- Marshall G. Radiography 2008; 14: 128-34.
- Gricar J et al. Radiol Manage 2007; SEP/OCT: 34-42.
- Dhaliwal H et al. Int J Life Cycle Assess 2014; 19: 1965-73.